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Acute liver failure (ALF) in infancy and childhood is a life-threatening emergency. Few conditions are known to cause recurrent acute
liver failure (RALF), and in about 50% of cases, the underlying molecular cause remains unresolved. Exome sequencing in five unrelated
individuals with fever-dependent RALF revealed biallelic mutations in NBAS. Subsequent Sanger sequencing of NBAS in 15 additional
unrelated individuals with RALF or ALF identified compound heterozygousmutations in an additional six individuals from five families.
Immunoblot analysis of mutant fibroblasts showed reduced protein levels of NBAS and its proposed interaction partner p31, both
involved in retrograde transport between endoplasmic reticulum and Golgi. We recommend NBAS analysis in individuals with acute
infantile liver failure, especially if triggered by fever.Acute liver failure (ALF) is a very severe, life-threatening
event which can result from toxin exposure, inherited
metabolic disease, autoimmune disease, infectious disease,
shock, and other rare causes. The exact incidence of pedi-
atric ALF is unknown, and in about 50% of cases the under-
lying cause remains obscure.1,2 Prognosis is guarded and
emergency liver transplantation is often the only thera-
peutic option. Known causes of recurrent acute liver failure
(RALF) with clinical and biochemical hepatic recovery in
the interval include fulminant viral hepatitis, autoimmune
hepatitis, disorders of long-chain fatty acid oxidation and
the carnitine cycle, dihydrolipoamide dehydrogenase
(E3) deficiency (MIM: 246900), and Wolcott-Rallison syn-
drome (MIM: 226980).3–7 Here we report the identification
of homozygous or compound heterozygous mutations in
NBAS (neuroblastoma amplified sequence) in 11 individ-
uals with RALF starting in infancy.
A group of four unrelated German individuals with
previously unclassified early-onset RALF (according to the
definition of the Pediatric Acute Liver Failure Study
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The AHospital Heidelberg) and jointly analyzed. Clinical and
genetic findings are summarized in Table 1. Informed con-
sent to participate in the study was obtained from all
affected individuals (or their parents, in the case of minor
study participants). The study was approved by the ethical
committees of the University Hospital Heidelberg and of
the Technische Universita¨t Mu¨nchen. Whole exome
sequencing was performed on genomic DNA from four un-
related affected individuals as described previously.8 Using
a frequency filter of minor allele frequency < 0.1% in our
in-house database and public databases, we identified six,
seven, three, and nine compound heterozygous or homo-
zygous variants in individuals F1:II.1, F2:II.1, F3:II.1, and
F4:II.3, respectively. NBAS (GenBank: NM_015909.3,
MIM: 608025) is the only gene where biallelic mutations
were identified in all affected individuals (Figure 1). In in-
dividual F5:II.2, presumably disease-causing mutations in
NBAS had been identified in a preceding exome sequence
analysis but the relevance of this finding had remained un-
clear. The analysis of exome sequencing data from approx-
imately 4,000 individuals with unrelated phenotypesen, Germany; 2Institute of HumanGenetics, Helmholtz ZentrumMu¨nchen,
Neuropediatrics and Metabolic Medicine, University Hospital Heidelberg,
eidelberg, 69120 Heidelberg, Germany; 5Children’s Hospital Reutlingen,
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H, UK; 8Institute of Human Genetics, University Hospital Heidelberg,
spital Heidelberg, 69120 Heidelberg, Germany; 10Ophthalmology Depart-
en’s Hospital Karlsruhe, 76133 Karlsruhe, Germany; 12Children’s Hospital
ndrial Research, Institute of Neuroscience, The Medical School, Newcastle
trics, Neonatology and Pediatric Cardiology, University Children’s Hospital,
sity of Pittsburgh School of Medicine, Children’s Hospital of Pittsburgh of
Medical University, 6020 Innsbruck, Austria; 17Computational Genomics,
s.org/licenses/by/4.0/).
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Table 1. Genetic and Clinical Findings in Individuals with NBAS Mutations
ID Sex
NBAS Mutations Protein Levels Fibroblasts Clinical Features
cDNA (NM_015909.3),
Protein (NP_056993.2) NBAS p31 AO
Age Last
Crisis
Number
of ALF
Age Last
Visit
Other Clinical
Findings
F1:II.1 F c.[558_560del];[686dup],
p.[Ile187del];[Ser230Glnfs*4]
21% 27% 21 14 9/12 years 2 18 years none reported
F2:II.1 F c.[2708T>G];[2708T>G],
p.[Leu903Arg];[Leu903Arg]
22% 30% 7 21 1/12 years 7 22 years acute renal failure,
epilepsy
F3:II.1 F c.[603_605del];[3164T>C],
p.[Leu202del];[Leu1055Pro]
20% 38% 10 11 7/12 years 5 18 years celiac disease
F4:II.3 F c.[2708T>G];[2827G>T],
p.[Leu903Arg];[Glu943*]
26% 38% 8 ND ND 37 years none reported
F5:II.2 M c.[3010C>T];[3164T>C],
p.[Arg1004*];[Leu1055Pro];
18% 33% 7 9 10/12 years 10 14 years cardiomyopathy
F6:II.1 M c.1533_1545del];[2951T>G],
p.[Ile512Thrfs*4];[Ile984Ser]
ND ND 18 3 11/12 years 5 3 years none reported
F7:II.1 F c.[1042C>T];[22033C>G],
p.[Pro348Ser];[?]
32% ND 11 6 7/12 years 4 9 years none reported
F7:II.2 F c.[1042C>T];[22033C>G],
p.[Pro348Ser];[?]
36% ND 6 8/12 years 6 8/12 years 1 11 years erythema nodosum,
Crohn’s disease
F8:II.2 M c.[1187G>A];[2330C>A],
p.[Trp396*];[Pro777His]
ND ND 21 3 years 1 8 years none reported
F9:II.2 F c.[1182A>G];[2524G>T],
p.[?(;)Val842Phe]
ND ND 18 2 2/12 years 3 4 years none reported
F10:II.1 F c.[686dup];[3164T>C],
p.[Ser230Glnfs*4];
[Leu1055Pro]
ND ND 4 5 10/12 years 5 18 years ND
NBAS and p31 protein levels are normalized to b-actin and are given in percent of a control cell line. Abbreviations are as follows: AO, age of onset (in months if not
stated otherwise); M, male; F, female; ND, not determined.(all subjects were sequenced in the Institute of Human
Genetics, Helmholtz Zentrum Mu¨nchen, and their data
stored in an in-house database) identified only one addi-
tional sample with two rare variants in NBAS potentially
compatible with a recessive disease. However, parental
samples were not available and a compound heterozygous
state of the two variants has not been confirmed. We sub-
sequently studied 15 additional unrelated individuals with
unresolved RALF and ALF from four additional clinical
centers by Sanger sequencing. Primer sequences and PCR
conditions for Sanger sequencing of NBAS are available
on request. This resulted in the identification of six addi-
tional individuals from five families with compound het-
erozygous mutations in NBAS (Figure 1). All 11 individuals
carry at least one missense mutation on one allele. All
missense mutations change evolutionarily conserved
amino acid residues (Figure 2) and are accordingly pre-
dicted to be damaging (PolyPhen-2 and SIFT). Carrier
testing showed that each parent analyzed was heterozy-
gous for one allele; the mother of individual F4:II.3 had
died before the study was performed so testing was impos-
sible and parental samples of individuals F8:II.2, F9:II.2,
and F10:II.1 were not available. Remarkably, in two fam-
ilies, F8 and F9, the oldest siblings had died in early infancy
due to acute liver failure, aged 14 and 11 months, respec-164 The American Journal of Human Genetics 97, 163–169, July 2, 20tively; however, no material was available to genetically
confirm their clinical diagnosis of NBAS deficiency.
Notably, all mutations, which are not predicted to cause
a loss of function, are clustered in two regions in the first
half of the gene, exons 8–12 and exons 21–28. The muta-
tions in the latter region affect the secretory pathway
sec39 domain of NBAS (Figure 2). Individual F2:II.1 carries
a homozygous missense variant and individual F3:II.1 an
in-frame deletion of one amino acid compound heterozy-
gous with a missense mutation. All other affected individ-
uals are compound heterozygotes for one out of seven
different predicted loss-of-function mutations (three stop
mutations, two frameshift, and two splice site mutations)
plus a missense mutation or a deletion of a single amino
acid. None of the NBAS missense mutations is present in
>120,000 alleles from the Exome Aggregation Consortium
(ExAC) Server (12/2014). Three of the loss-of-function
mutations, c.686dup (p.Ser230Glnfs*4), c.2827G>T
(p.Glu943*), and c.3010C>T (p.Arg1004*), are listed in
the heterozygous state 593, 83, and 13, respectively
(MAF < 0.04%). Although we have no indication for a
shared haplotype for the c.3164T>C variant identified het-
erozygous in three families, the exome data suggests a
common founder c.2708T>G mutation in German fam-
ilies 2 and 4.15
Figure 1. Pedigrees of Investigated Families
Pedigrees of ten families affected by RALF and mutations in NBAS. Mutation status of affected (closed symbols) and healthy (open sym-
bols) family members.Next, the functional consequences of NBAS mutations
on the protein level were investigated. In eukaryotic cells,
soluble N-ethylmaleimide-sensitive factor attachment
protein receptor (SNARE) tethering factors mediate the
docking and fusion of transport vesicles with target mem-
branes. Fusion of membranes is mediated by membrane-
bound proteins on the transport vesicles (v-SNARE) and
target membrane (t-SNARE). NBAS is thought to function
as a component of an ER tethering complex that interacts
with the t-SNAREs p31, BNIP1, and STX18 at the ER and
the v-SNARE Sec22b. This tethering complex also includes
ZW10, RINT1, and Sly1 (see Figure S1).9,10 Mutant and
control fibroblasts were cultivated in D-MEM media sup-
plemented with 10% FBS, 1% penicillin-streptomycin,
and 200 mM uridine at 37C and 5% CO2. For immuno-
blots, cells were collected, washed in PBS, and resolved in
RIPA buffer.11 10 mg of protein of every sample were sepa-
rated on a 4%–12% acrylamide gradient gel (LONZA).
Primary antibodies (all Sigma-Aldrich) against NBAS
(1:2,000), p31 (USE-1) (1:250), and b-actin (1:15,000)
were incubated overnight. Enhanced chemiluminescence
of proteins was detected with a Vilberscan Fusion FX7.
Protein levels were quantified with the software Bio-1D.
Testing of individual F1:II.1 fibroblasts showed a signifi-
cant decrease in NBAS steady-state levels (p ¼ 0.03;
two-tailed unpaired t test). Extending the quantification
of NBAS protein to affected individuals from families
2–5 and 7 showed a reduction of NBAS levels to 18%–
36% in comparison to controls, indicating a substantialThe Aimpairment of protein translation and/or stability in all
seven affected individuals investigated (Figure 3 shows
representative findings for individuals from families 1–5).
Moreover, the reduction of NBAS was concomitant with
a reduction of its proposed interaction partner p31,
supporting an important function of NBAS within the
syntaxin 18 complex (Figure S1). None of the additional
components have been associated with a human disorder.
Mouse models of deleted p31 and RINT1 were shown to be
embryonic lethal.12,13
Next, we investigated whether an assumed defect in the
assembly of the ER tethering complex impairs glycosyla-
tion and/or results in increased ER stress. Isoelectric
focusing of transferrin, alpha-1-antitrypsin, and apolipo-
protein CIII followed by in-gel immunodetection was
performed in sera of a control subject, a COG6-CDG
individual, and five individuals with NBAS mutations.
Although the observed patterns indicated a clear defi-
ciency in N-/O-glycosylation in the CDG individual, no
differences were observed for theNBAS-mutant individuals
compared to controls (Figure S2). These findings suggest
that under the investigated conditions NBAS deficiency
does not disturb retrograde transport between ER and
Golgi to the extent that obvious changes in glycosylation
patterns can be observed.
We next performed expression profiling inNBAS-mutant
fibroblast to test for alterations suggestive for ER stress.
Total cellular RNA was isolated from fibroblasts of three
NBAS-affected individuals (F1:II.1, F2:II.1, F5:II.2) andmerican Journal of Human Genetics 97, 163–169, July 2, 2015 165
Figure 2. NBAS Structure and Conservation of Identified Mutations
Gene structure of NBAS with known protein domains of the gene product and localization and conservation of amino acid residues
affected by mutations. Mutation c.5741G>A (p.Arg1914His) in exon 45 in the C-terminal domain of unknown function is associated
with SOPH syndrome.17 Amino acids 90–371 form a quinoprotein aminedehydrogenase, beta chain like domain (IPR011044) and amino
acids 725–1,376 form a secretory pathway sec39 domain (IPR013244). Intronic regions are not drawn to scale.12 healthy controls. The quality of the RNA isolated from
whole-cell lysates was determined with the Agilent 2100
BioAnalyzer (RNA 6000 Nano Kit, Agilent). All samples
had a RNA integrity number (RIN) value greater than 8.
RNA libraries were sequenced as 100 bp paired-end runs
on an Illumina HiSeq2500 platform as described.14 In or-
der to get expression measurements, we counted reads
with HTSeq-count using the intersection-strict option on
20,345 protein coding genes from the Gencode database
(GRCh37, p13, 19.07.2013).15 Read counts were normal-
ized with size factors computed by DESeq2 to account for
differences in sequencing depth per sample.16 We dis-
carded genes with an average normalized expression below
10 over all samples and performed all consecutive analysis
on the remaining 13,392 genes. Although there was no
global change in gene expression, we did observe a signif-
icant increase in the expression of genes involved in ER
stress response in NBAS-mutant fibroblasts compared to
controls (Figure 4).
Together, our genetic and experimental findings provide
evidence that mutations affecting functionally conserved
domains in NBAS resulting in severely decreased NBAS
levels cause RALF in infancy. Although no changes in
glycosylation patterns were observed in the conditions
investigated, expression profiles in NBAS mutant fibro-
blasts are suggestive for ER stress. RALF due to mutated
NBAS is a presumably relatively frequent inherited cause
of RALF, because NBAS screening of 15 individuals with
RALF or acute infantile liver failure resulted in the discov-
ery of six affected individuals from five additional families.
The pivotal feature of this disease is RALF precipitated by
intercurrent febrile illnesses during infancy and child-166 The American Journal of Human Genetics 97, 163–169, July 2, 20hood. Intriguingly, with conservative management, liver
function recovered completely and was normal in the
interval. Crises are heralded by vomiting and lethargy
and start rather uniformly with massively elevated ASAT
and ALAT (range of maximum ALAT 4,001–17,700 U/l;
normal < 50 U/l), followed by coagulopathy requiring
FFP substitution (maximum INR 10; normal < 1.2) and
mild to moderate jaundice (range of maximum total
bilirubin 46.8–207.4 mmol/l; normal < 20.4 mmol/l). In
some cases, significant hypoglycemia, hyperammonemia
(maximum 209 mmol/l; normal < 53 mmol/l), and hepatic
encephalopathy developed, which we consider to be
secondary to ALF. Several affected individuals suffered
from a range of comorbidities including cardiomyopathy,
autoimmune gastrointestinal diseases, and neurological
phenotypes such as epilepsy. However, none of those
conditions is present in two individuals (Table 1).
Mutations in NBAS have not been linked to liver disease
before, but a homozygous missense mutation c.5741G>A
(p.Arg1914His) in the C-terminal domain of unknown
function of NBAS has been associated with a syndrome
of short stature, cone and optic nerve atrophy, and
Pelger-Hue¨t anomaly in Yakuts (SOPH syndrome [MIM:
614800]).17 RALF-causing NBAS deficiency and SOPH syn-
drome are clearly different clinical entities. Importantly,
individuals with SOPH syndrome were not reported to
have ALF or any hepatic disease manifestation and the
impact of the SOPH-associated mutation on NBAS protein
function is unknown.
None of the individuals with NBAS-induced (R)ALF car-
ried two loss-of-function mutations in NBAS. However,
NBAS mutations led to low levels of the gene product of15
Figure 3. Quantification of NBAS and p31 Protein Levels
Mutant and control fibroblast cell lines were cultivated at 37C.
10 mg protein of collected cells were separated on a 4%–12% acryl-
amide gradient gel, transferred to a PVDF membrane, and immu-
nodecorated with antibodies against NBAS, p31, and b-actin.
The antibody for NBAS was detecting a single protein band at
approximately 270 kDa corresponding to the predicted molecular
weight of NBAS. b-actin was used as a loading control. The quan-
tified protein levels are based on three independent experiments
and expressed as percentages of a control cell line, corrected for
b-actin. Five of the eight investigated subject cell lines are shown.
NBAS and p31 protein levels were severely reduced in fibroblast
cell lines of RALF-affected individuals to 21% and 33% of control
subjects, respectively. Error bar indicates 1 SD. Protein amount in
control 1 was set as 100%.
Figure 4. Increased Expression of ER Stress Response Genes
Quartiles (boxes) and 1.5 times the interquartile range (whiskers)
of the fold change of normalized RNA-seq read counts from fibro-
blasts are displayed. Three individuals with pathogenic variants
in NBAS (F1:II.1, F2:II.1, and F5:II.2) are compared against the
median per gene over 12 control samples.We obtained interaction
partners of the NBAS protein from the BioGrid database (v.3.3).18
The genes associated with the corresponding gene ontology
terms were downloaded from UniProt (accessed March 2015).19
For every box, we computed a two-sided Wilcoxon test whether
it is symmetric about 1. Single data points are shown for
boxes with less than 50 genes. Gene ontology (GO) terms:
GO 0034976, response to endoplasmic reticulum stress; GO
0001889, liver development; GO 0006259, DNA metabolic pro-
cess; GO 0006119, oxidative phosphorylation. ns, p > 0.1.about 25% NBAS protein (compared to healthy probands).
The affected individuals recovered completely in the inter-
vals between the crises and otherwise presented a rather
mild phenotype, so reduced NBAS protein levels due to
the mutations appear to be sufficient for normal function
of most tissues including liver under afebrile conditions.
The physiologic function of NBAS is not yet understood.
In yeast, sec39 is involved in retrograde transport between
ER and Golgi.9 Aoki et al.9 provided evidence for a similar
function of NBAS in humans where it is interacting with
p31. Together with other SNARE proteins, they are forming
the syntaxin 18 complex implicated in ER membrane
fusion. Concomitant with reduced NBAS levels, p31 levels
were also decreased, providing additional evidence that
both proteins are subunits of the same SNARE complex.
Similar findings were observed after targeted knockdown
in HeLa cells.9 The exact mechanism of ALF due to NBASThe Adeficiency remains unclear.We reason that a catabolic state
with high energy demand during febrile infections or the
raised temperature itself might be the starting points of
the derailment, speculatively via a thermal susceptibility
of the syntaxin 18 complex.
In contrast to acute infantile liver failure resulting
from mutations in TRMU (MIM: 613070), MARS (MIM:
615486), or LARS (MIM: 615438), NBAS deficiency was
not associated with increased serum lactate or muscular
hypotonia. In about 50% of cases of acute infantile liver
failure, the underlying cause remains undetermined.
Some of these children might have an underlying genetic
disorder or predisposition. The detection rate of NBAS
mutations in random individuals with (recurrent) acute
infantile liver failure was very high (6 out of 15 screened
individuals), so NBAS deficiency might be a frequent cause
of not only RALF but also isolated ALF at least in children.
The differing genetic origins of affected individuals and
variety of mutations suggest that this autosomal-recessive
disease is not a regional phenomenon.
In conclusion,mutations inNBAS are delineated as a pre-
viously unknown cause of acute liver failure with onset in
childhood triggered by febrile infections. It is possible that
the affected individuals reported in this study present themerican Journal of Human Genetics 97, 163–169, July 2, 2015 167
severe end of the phenotypic spectrum. Notably, in fam-
ilies F8 and F9, two older siblings had died from acute liver
failure, aged 14 and 11months. Unfortunately, nomaterial
was available for diagnostics from the deceased individ-
uals. However, the finding of NBASmutations in their sib-
lings suggests NBAS-induced ALF. Hence, these individuals
might provide examples for a lethal course of NBAS defi-
ciency. We recommended sequencing NBAS in cases of
ALF in infancy and childhood of unknown cause, espe-
cially in individuals with fever-associated ALF and/or RALF.Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.ajhg.2015.05.009.Acknowledgments
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